Do analysts recommend IMA or ANEB?

ImageneBio presently has a consensus target price of $29.00, suggesting a potential upside of 530.43%. Given ImageneBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImageneBio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMA or ANEB more profitable?

ImageneBio's return on equity of -38.99% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate BKHA or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BKHA or ANEB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is BKHA or ANEB more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate TIL or ANEB?

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 3.05%. Given Instil Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Instil Bio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, TIL or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is TIL or ANEB more profitable?

Instil Bio's return on equity of -26.78% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts prefer ANEB or ELTX?

Elicio Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 681.25%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, ANEB or ELTX?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A

Is ANEB or ELTX more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Elicio Therapeutics N/A -1,266.43% -139.94%

Do analysts prefer HOWL or ANEB?

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 330.99%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Werewolf Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.32 0.00 (0.00%)

As of 10/2/2026 10:40 AM Eastern

Compare

ANEB vs. IMA, BKHA, TIL, ELTX, and HOWL

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? Anebulo Pharmaceuticals's main competitors and comparable companies include ImageneBio (IMA), Black Hawk Acquisition (BKHA), Instil Bio (TIL), Elicio Therapeutics (ELTX), and Werewolf Therapeutics (HOWL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anebulo Pharmaceuticals compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, ImageneBio had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for ImageneBio and 0 mentions for Anebulo Pharmaceuticals. ImageneBio's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ImageneBio	Neutral
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals has lower revenue, but higher earnings than ImageneBio. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

ImageneBio presently has a consensus target price of $29.00, suggesting a potential upside of 530.43%. Given ImageneBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImageneBio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ImageneBio's return on equity of -38.99% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

ImageneBio has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its share price is 288% less volatile than the broader market.

Summary

ImageneBio beats Anebulo Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Black Hawk Acquisition's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Black Hawk Acquisition has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its share price is 288% less volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, Black Hawk Acquisition's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Black Hawk Acquisition	Neutral
Anebulo Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Black Hawk Acquisition beats Anebulo Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Instil Bio currently has a consensus price target of $7.00, indicating a potential downside of 3.05%. Given Instil Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Instil Bio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Instil Bio's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Instil Bio	Neutral
Anebulo Pharmaceuticals	Neutral

Instil Bio's return on equity of -26.78% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market.

Summary

Instil Bio beats Anebulo Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Elicio Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Elicio Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 681.25%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Elicio Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Elicio Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 beat Elicio Therapeutics' score of -0.53 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Elicio Therapeutics	Negative

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Anebulo Pharmaceuticals' return on equity of -74.57% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Summary

Elicio Therapeutics beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 330.99%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Werewolf Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Werewolf Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, meaning that its stock price is 288% less volatile than the broader market.

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Werewolf Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	23.99	-$60.82M	-$0.76	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Werewolf Therapeutics' average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Anebulo Pharmaceuticals	Neutral

Summary

Werewolf Therapeutics beats Anebulo Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.05M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.68	13.00	274.71	26.04
Price / Sales	N/A	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.14	16.57	10.93	6.31
Net Income	-$8.48M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-1.54%	-2.97%	-2.00%	-1.66%
1 Month Performance	-10.76%	-10.82%	-6.19%	-4.68%
1 Year Performance	-86.15%	19.00%	8.03%	1.57%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	0.0329 of 5 stars	$0.32 flat	N/A	-86.1%	$13.05M	N/A	N/A	4
IMA ImageneBio	2.6588 of 5 stars	$4.58 flat	$29.00 +533.2%	-46.5%	$51.99M	$800K	N/A	18	News Coverage Gap Up
BKHA Black Hawk Acquisition	N/A	$12.25 -0.9%	N/A	+9.8%	$51.34M	N/A	N/A	N/A
TIL Instil Bio	0.3378 of 5 stars	$7.24 +1.4%	$7.00 -3.3%	-60.1%	$48.42M	N/A	N/A	410
ELTX Elicio Therapeutics	2.3438 of 5 stars	$1.82 -1.1%	$15.00 +724.2%	-82.7%	$48.36M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. IMA, BKHA, TIL, ELTX, and HOWL

How does Anebulo Pharmaceuticals compare to ImageneBio?

Summary

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Summary

How does Anebulo Pharmaceuticals compare to Instil Bio?

Summary

How does Anebulo Pharmaceuticals compare to Elicio Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Werewolf Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. IMA, BKHA, TIL, ELTX, and HOWL

How does Anebulo Pharmaceuticals compare to ImageneBio?

Does the media refer more to IMA or ANEB?

Which has preferable valuation & earnings, IMA or ANEB?

Do analysts recommend IMA or ANEB?

Do insiders & institutionals have more ownership in IMA or ANEB?

Is IMA or ANEB more profitable?

Which has more volatility & risk, IMA or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Black Hawk Acquisition?

Is BKHA or ANEB more profitable?

Which has more risk and volatility, BKHA or ANEB?

Do institutionals & insiders believe in BKHA or ANEB?

Which has higher earnings & valuation, BKHA or ANEB?

Does the media refer more to BKHA or ANEB?

Do analysts rate BKHA or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Instil Bio?

Do analysts rate TIL or ANEB?

Does the media refer more to TIL or ANEB?

Is TIL or ANEB more profitable?

Do institutionals and insiders believe in TIL or ANEB?

Which has preferable valuation & earnings, TIL or ANEB?

Which has more volatility and risk, TIL or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Elicio Therapeutics?

Do institutionals & insiders hold more shares of ANEB or ELTX?

Which has more volatility and risk, ANEB or ELTX?

Do analysts prefer ANEB or ELTX?

Does the media prefer ANEB or ELTX?

Which has better valuation and earnings, ANEB or ELTX?

Is ANEB or ELTX more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Werewolf Therapeutics?

Is HOWL or ANEB more profitable?

Do analysts prefer HOWL or ANEB?

Do institutionals and insiders hold more shares of HOWL or ANEB?

Which has more volatility & risk, HOWL or ANEB?

Which has better earnings & valuation, HOWL or ANEB?

Does the media refer more to HOWL or ANEB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools